EndoTODAY | EndoATLAS | OPD

Parasite | Eso | Sto | Cancer | ESD

Boxim | DEX | Sono | Schedule

Home | Recent | Blog | Links

EndoTODAY ³»½Ã°æ ±³½Ç


[EsoTODAY 050 - Proton therapy for esophageal cancer. ¾ç¼ºÀÚÄ¡·á] - ðû

Previous | Next

¼º±Õ°üÀÇ´ë ÇмúÀâÁö Precision and Future Medicine¿¡ Proton therapy¿¡ ´ëÇÑ ¸ÚÁø ¸®ºä°¡ ½Ç·È½À´Ï´Ù (PFM 2019).

Proton therapy´Â X-ray¸¦ ÀÌ¿ëÇÑ photon therapy¿Í´Â »ç¹µ ´Ù¸¥ ¹°¸®Àû Ư¼ºÀÌ ÀÖ½À´Ï´Ù. ProtonÀÇ ¿¡³ÊÁö´Â ƯÁ¤ ±íÀÌ¿¡ ¸ðÀÔ´Ï´Ù (Bragg peak). µû¶ó¼­ target ÀÌ¿ÜÀÇ Á¶Á÷¿¡ ¹ÌÄ¡´Â ¿µÇâÀÌ ¸Å¿ì Àû½À´Ï´Ù.

The width of the Bragg peak is narrow; thus, it needs to be spread out to cover the tumor volume longitudinally ("spread-out Bragg peak").


[½Äµµ¾Ï¿¡¼­ÀÇ ¼ºÀû]

Investigators at the MD Anderson Cancer Center reported that in patients treated with neoadjuvant chemotheradiation followed by surgery, there was a significant increase in pulmonary complications for 3D-CRT (three dimensional conformal radiation therapy) and a trend for IMRT (intensity-modulated radiation therapy) compared with that for proton therapy.

In a recent study, the treatment outcomes of proton therapy for locally advanced esophageal cancer were better than those of IMRT. A total of 343 patients who received definitive chemoradiation with either proton therapy (n=132) or IMRT (n=211) were analyzed retrospectively. Proton therapy resulted in significantly better OS (P=0.01), PFS (P=0.0001), and locoregional failure-free survival (P=0.041) in multivariate analysis. In stage III disease, 5-year OS (34.6% vs. 25.0%, P=0.038) and PFS (33.5% vs. 13.2%, P=0.005) rates were higher in the proton therapy group, while there were no significant differences in survival for Stage I/II patients.


[ÁßÀÔÀÚ Ä¡·á carbon therapy]

2023-6-21. À§¾Ï¼¾ÅÍ È¸ÀÇ

© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng. (since 1999-8-23)